KindredBio Announces Initiation of Pivotal Clinical Study for AtoKin™ in Dogs
AtoKin™, KindredBio’s second lead product, is expected to be a major advance in the treatment of symptoms associated with atopic dermatitis.
SAN FRANCISCO, California. (February 20, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has initiated a pivotal clinical trial for AtoKin (KIND-002) in dogs with atopic dermatitis. The trial is being conducted at veterinary sites across the United States and, if positive, is expected to lead to the approval of AtoKin by 2015.
